Model AZD3366 - Phase I -Cardiovascular Disease

Mechanism: CD39L3. Area under investigation: cardiovascular disease. Date commenced phase: Q4 2020. Estimated Filing Acceptance: Country:US, EU, Japan, China, Additional information: Molecule size: Small molecule. Status change: